Viroporiners potentiale som lægemiddeltargets med fokus på SARS-CoV-2
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 666 KB, PDF-dokument
Viroporins are ion channels found in many viruses, where they contribute to virus life cycle and thereby pathogenesis. Viroporin targeting is a known, yet largely unexplored, therapeutic strategy so far only used in Influenza A with the drugs amantadine and rimantadine. In this review, we seek to utilize the inhibition by amantadine of the viroporin Protein E in SARS-CoV-2 in an attempt to treat COVID-19 in its early stages. We are executing a double-blinded placebo-controlled trial based on promising in vivo and in vitro work as a stepping-stone for establishing a therapeutic antiviral regime: blocking of viroporins.
Bidragets oversatte titel | The antiviral targeting potential of viroporins |
---|---|
Originalsprog | Dansk |
Artikelnummer | V02220103 |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 184 |
Udgave nummer | 24 |
Antal sider | 8 |
ISSN | 0041-5782 |
Status | Udgivet - 13 jun. 2022 |
- Amantadine, Antiviral Agents/pharmacology, COVID-19/drug therapy, Humans, SARS-CoV-2, Viroporin Proteins
Forskningsområder
Links
- https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-06/v02220103_web.pdf
Forlagets udgivne version
ID: 327399766